# EDGAR Filing Document

**Accession Number:** 0001601830
**File Stem:** 0001209191-23-002460
**Filing Date:** 2023-1
**Character Count:** 11480
**Document Hash:** 94014de479252a908afaeaefde11ee8e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-002460.hdr.sgml**: 20230106

**ACCESSION NUMBER**: 0001209191-23-002460

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230105

**FILED AS OF DATE**: 20230106

**DATE AS OF CHANGE**: 20230106

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Gibson Christopher
- **CENTRAL INDEX KEY:** 0001856369

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40323
- **FILM NUMBER:** 23516189

**MAIL ADDRESS:**
- **STREET 1:** C/O RECURSION PHARMACEUTICALS
- **STREET 2:** 41 S. RIO GRANDE STREET
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84101
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RECURSION PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001601830
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 464099738
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 41S RIO GRANDE STREET
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84101
- **BUSINESS PHONE:** (385) 269-0203

**MAIL ADDRESS:**
- **STREET 1:** 41S RIO GRANDE STREET
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84101

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Recursion Pharmaceuticals, LLC
- **DATE OF NAME CHANGE:** 20140305

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Gibson Christopher<br><sub>(Last) (First) (Middle)</sub><br>C/O RECURSION PHARMACEUTICALS<br>41 S. RIO GRANDE STREET<br><sub>(Street)</sub><br>SALT LAKE CITY, UT 84101<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-05 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>RECURSION PHARMACEUTICALS, INC. [ RXRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class A Common Stock | 2022-04-25 |  | G<sup>(1)</sup> | V | 12000 | D | $0.00 | 570805 | D |  |
| Class A Common Stock | 2022-05-12 |  | G<sup>(1)</sup> | V | 12000 | D | $0.00 | 558805 | D |  |
| Class A Common Stock | 2022-05-19 |  | G<sup>(1)</sup> | V | 12000 | D | $0.00 | 546805 | D |  |
| Class A Common Stock | 2022-06-21 |  | G<sup>(1)</sup> | V | 3000 | D | $0.00 | 543805 | D |  |
| Class A Common Stock | 2022-07-19 |  | G<sup>(1)</sup> | V | 3000 | D | $0.00 | 540805 | D |  |
| Class A Common Stock | 2022-08-17 |  | G<sup>(1)</sup> | V | 3000 | D | $0.00 | 537805 | D |  |
| Class A Common Stock | 2022-09-19 |  | G<sup>(1)</sup> | V | 3000 | D | $0.00 | 534805 | D |  |
| Class A Common Stock | 2022-10-19 |  | G<sup>(1)</sup> | V | 3000 | D | $0.00 | 531805 | D |  |
| Class A Common Stock | 2022-11-16 |  | G<sup>(1)</sup> | V | 3000 | D | $0.00 | 528805 | D |  |
| Class A Common Stock | 2022-12-14 |  | G<sup>(1)</sup> | V | 3000 | D | $0.00 | 525805 | D |  |
| Class A Common Stock | 2023-01-05 |  | C<sup>(1)(2)</sup> |  | 18500 | A | $0.00 | 544305 | D |  |
| Class A Common Stock | 2023-01-05 |  | S<sup>(1)</sup> |  | 18500 | D | 7.3875<sup>(3)</sup> | 525805 | D |  |
| Class A Common Stock | 2023-01-05 |  | C<sup>(1)(2)</sup> |  | 500 | A | $0.00 | 500 | I | by LAHWRAN-3 LLC<sup>(4)</sup> |
| Class A Common Stock | 2023-01-05 |  | S<sup>(1)</sup> |  | 500 | D | 7.3789<sup>(5)</sup> | 0 | I | by LAHWRAN-3 LLC<sup>(4)</sup> |
| Class A Common Stock | 2023-01-05 |  | C<sup>(1)(2)</sup> |  | 1000 | A | $0.00 | 1000 | I | by LAHWRAN-4 LLC<sup>(6)</sup> |
| Class A Common Stock | 2023-01-05 |  | S<sup>(1)</sup> |  | 1000 | D | 7.3907<sup>(7)</sup> | 0 | I | by LAHWRAN-4 LLC<sup>(6)</sup> |
| Class A Common Stock | 2023-01-05 |  | C<sup>(1)(2)</sup> |  | 1000 | A | $0.00 | 1000 | I | by Gibson Family Trust<sup>(8)</sup> |
| Class A Common Stock | 2023-01-05 |  | S<sup>(1)</sup> |  | 1000 | D | 7.3822<sup>(9)</sup> | 0 | I | by Gibson Family Trust<sup>(8)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Class B Common Stock | $0.00 | 2023-01-05 |  | C<sup>(1)(2)</sup> |  |  | 18500 | <sup>(10)</sup> | <sup>(10)</sup> | Class A Common Stock | 18500 | $0.00 | 6658834 | D |  |
| Stock Option (Right to Buy) | $11.40 |  |  |  |  |  |  | <sup>(11)</sup> | 2032-02-04 | Class A Common Stock | 0 |  | 416350 | D |  |
| Stock Option (Right to Buy) | $11.40 |  |  |  |  |  |  | 2022-02-04 | 2032-02-04 | Class A Common Stock | 0 |  | 5436 | D |  |
| Stock Option (Right to Buy) | $2.48 |  |  |  |  |  |  | <sup>(12)</sup> | 2030-12-30 | Class A Common Stock | 0 |  | 781250 | D |  |
| Class B Common Stock | $0.00 | 2023-01-05 |  | C<sup>(1)(2)</sup> |  |  | 500 | <sup>(10)</sup> | <sup>(10)</sup> | Class A Common Stock | 500 | $0.00 | 540000 | I | by LAHWRAN-3 LLC<sup>(4)</sup> |
| Class B Common Stock | $0.00 | 2023-01-05 |  | C<sup>(1)(2)</sup> |  |  | 1000 | <sup>(10)</sup> | <sup>(10)</sup> | Class A Common Stock | 1000 | $0.00 | 530000 | I | by LAHWRAN-4 LLC<sup>(6)</sup> |
| Class B Common Stock | $0.00 | 2023-01-05 |  | C<sup>(1)(2)</sup> |  |  | 1000 | <sup>(10)</sup> | <sup>(10)</sup> | Class A Common Stock | 1000 | $0.00 | 126875 | I | by Gibson Family Trust<sup>(8)</sup> |

---

### Footnotes:

(1) Transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

(2) Represents the conversion of Class B Common Stock into Class A Common Stock.

(3) This transaction was executed in multiple trades at prices ranging from $7.29 to $7.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

(4) The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.

(5) This transaction was executed in multiple trades at prices ranging from $7.30 to $7.67. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

(6) The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.

(7) This transaction was executed in multiple trades at prices ranging from $7.33 to $7.67. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

(8) The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.

(9) This transaction was executed in multiple trades at prices ranging from $7.30 to $7.67 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

(10) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

(11) The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

(12) The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

**Signature:** /s/ Jonathan Golightly, attorney-in-fact  
**Date:** 2023-01-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**